15 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
3 Dec 18
Other Events
4:03pm
in breastfed children, advise women not to breastfeed during treatment with TIBSOVO and for at least 1 month after the last dose.
Please see full Prescribing … the last dose. Pregnant women, patients becoming pregnant while receiving IDHIFA, or male patients with pregnant female partners should be apprised
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
17 Apr 14
Other Events
12:00am
, placebo-controlled clinical trial will assess the safety and tolerability of AG-348 through dose escalation in healthy adult men and women. Key
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 May 19
Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma
4:13pm
of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVO® and for at least 1 month after the last
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
are excreted in human milk and because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
21 Sep 20
Other Events
7:14am
reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVO® and for at least 1 month after the last dose.
Please see
8-K
EX-99.2
fcxevddhh g4wim7r
3 Dec 18
Other Events
4:03pm
8-K
EX-99.1
1ho4cwnvu27p ksi
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
l4q7czshc03m0kzck7w
20 Jul 18
FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients
11:21am
8-K
EX-99.1
dvvc49wo j7nzny
22 Nov 19
Other Events
5:01pm
8-K
EX-99.1
0nyy6on95omxh
3 Jun 19
Other Events
4:02pm
8-K
EX-99.1
12fsca42a27b1s5iyls
2 May 19
Other Events
3:24pm
8-K
EX-99.1
wlzsxk
16 Oct 15
Regulation FD Disclosure
12:00am
- Prev
- 1
- Next